Professor Andrew Chang AM is one of 10 retina thought leaders from around the world to be appointed to Opthea’s new Medical Advisory Board (MAB).
The clinical-stage biopharmaceutical company, developing novel therapies to treat highly prevalent and progressive retinal diseases including neovascular agerelated macular degeneration (nAMD), has formed the MAB to advise on opportunities to address the unmet medical needs of patients with retinal diseases. Additionally, the MAB will inform the company’s development efforts, such as the sozinibercept clinical program in nAMD.
Chaired by Dr Arshad Khanani, Chief Medical Advisor of Opthea, MAB members come from the United States, Argentina, Australia, China, France, Germany, and Israel.
“We appreciate the support from world-renowned experts in retinal diseases to advise us on the shortand long-term strategic direction of our pipeline and development efforts,” said Frederic Guerard, Chief Executive Officer of Opthea.
The formation of the MAB comes at a crucial stage for Opthea as it prepares for Phase 3 topline data read-out of its two pivotal trials of sozinibercept in nAMD (COAST in early 2025 and ShORE in mid- 2025) and continues to advance regulatory and go-tomarket preparations.
Along with Prof Chang and Dr Khanani, the MAB comprises: Professor David S. Boyer (US), Professor Frank G. Holz (Germany), Professor Anat Loewenstein (Israel), Dr Dante Pieramici and Professor Carl Regillo (US), Professor Patricio G. Schlottmann (Argentina), Professor Tien Y. Wong (China), and Professor Eric Souied (France).